DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for testicular carcinoma — screening already-approved drugs against its 32-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleTesticular carcinoma maps to a 32-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for testicular carcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
hematopoietic prostaglandin D synthase (HPGDS) — HPGDS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gshdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7JR8 · 1.13 Å · ligand Glutathione (GSH). Experimental structure, not a prediction.
What the evidence adds up to
In a Danish study covering 1976 to 1980, 499 patients with non-seminomatous testicular germ cell tumours were followed. The 3-year crude survival for clinical stages I, II and III was 91, 77 and 45 per cent, respectively. For stage I patients, adding bleomycin and vincristine to radiation improved relapse-free survival compared to radiation alone, but crude survival did not differ. For stage II patients, maintenance chemotherapy after radiation plus bleomycin and vincristine did not improve relapse-free or crude survival. Survival improved over the five-year period, which the authors attributed to the introduction of cis-platinum.
Two case reports from 1994 describe testicular tumours in non-twin brothers from a cancer-prone family. Cytogenetic studies and HLA typing of the family failed to identify any genetic defects. The authors suggested linkage analysis would require additional families. A 1997 review notes that testicular carcinoma presents as a testicular abnormality in 90 per cent of cases, while 10 per cent of patients present with metastatic manifestations such as abdominal mass, haemoptysis, adenopathy, respiratory difficulty, anorexia, nausea, vomiting, lumbar back pain, or lower extremity swelling. One unique case presented with spontaneous ejaculatory failure.
A 1969 review article analysed cytogenetic and molecular markers for testicular germ cell tumours. The isochromosome i(12p) is the most common cytogenetic finding, appearing in carcinoma in situ. Proto-oncogenes including cyclin D and PTHLH, and putative tumour suppressor genes, are localised on 12p, but their role in pathogenesis and prognosis is not defined. Familial cases suggest a genetic background, but the genetic basis remains unknown. Most data on proliferation markers, tumour suppressor genes, proteases and adhesion molecules require confirmation in prospective randomised trials before widespread clinical use. Based on prospective studies, the percentage of embryonal carcinoma and vascular invasion appear to be the most significant prognosticators.
What is still missing are prospective randomised trials to validate molecular prognostic markers, larger family collections for genetic linkage studies, and a defined role for the genes on 12p in pathogenesis and prognosis. No drug repurposing data for testicular carcinoma are present in these abstracts.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Acta Radiologica Oncology · 1984 · 19 citations
Non-Seminomatous Testicular Germ Cell Tumours in Denmark 1976–1980 Results of Treatment
AbstractOver a 5-year period (1976-1980) 499 patients with non-seminomatous testicular germ cell tumours were included in the Danish Testicular Carcinoma Study (DATECA). The 3-year crude survival for patients in clinical stages I, II and III was 91, 77 and 45 per cent, respectively. In stage I the relapse-free survival for patients given radiation combined with bleomycin and vincristine was significantly higher than that for patients given radiation alone. No difference in the crude survival was observed. For stage II patients maintenance chemotherapy following radiation combined with bleomycin and vincristine did not improve relapse-free or crude survival. The survival of patients with non-seminomatous tumours improved significantly during the 5-year period. This improvement was probably due to the introduction of cis-platinum in the treatment.
Australian and New Zealand Journal of Surgery · 1994 · 5 citations
FAMILIAL TESTICULAR CARCINOMA: IN SEARCH OF GENETIC TRIGGERS
AbstractTwo cases of testicular tumours in non-twin brothers of a cancer-prone family are described. Cytogenetic studies of these two patients and human leucocyte antigen (HLA) typing of the family failed to identify any genetic defects. The authors propose using linkage analysis for further genetic studies but would require additional families for this to be performed.
Journal of diagnostic medical sonography · 1997 · 3 citations · open access
Typical and Atypical Presentations of Testicular Carcinoma
AbstractTesticular carcinoma most commonly presents as a testicular mass. Approxiately 10-15% of patients, however, present with manifestations of metastatic disease. The reported clinical presentations of metastatic testicular carcinoma are varied and include abdominal mass, hemoptysis, adenopathy, respiratory difficulty, anorexia, nausea, vomiting, lumbar back pain, and lower extremity swelling. A comprehensive review of the literature indicated that testicular carcinoma presents as a testicular abnormality 90% of the time. In 10% of cases, however, the patients will present with nontesticular manifestations of metastatic disease. The authors provide a summary of reported nontesticular presentations of testis cancer and describe a unique case wherein the clinical presentation was spontaneous ejaculatory failure.
Estimation of ascorbic acid on the basis of its reducing action in a Landolt system.
AbstractAim of this review article was to critically analyze the recently described cytogenetic and molecular markers for testicular germ cell tumors with regard to their clinical utility. The isochromosme i(12p) represents the most common and characteristic cytogenetic finding which already appears in testicular carcinoma in situ. A number of proto-oncogenes (cyclin D and PTHLH) as well as putative tumor suppressor genes are localized on 12p; however, their role in pathogenesis and prognosis of testicular germ cell tumors has not been defined yet. Clinical characteristics of patients with familial testicular germ cell tumors indicate a genetic background for the development of testicular tumors. Although a number of chromosomal loci encoding potential testicular tumor susceptibility genes have been identified, the genetic basis of testicular cancer pathogenesis is still unknown. With regard to molecular prognostic risk factors most of the reported data on proliferation markers, tumor suppressor genes, proteases and adhesion molecules have to be confirmed in prospective randomized trials prior to their widespread clinical use. Based on the available data on prospective studies the percentage of embryonal carcinoma and vascular invasion appear to be the most significant prognosticators. Investigation and identification of those factors determining the aggressive biologic behavior of embryonal carcinoma compared to all other histological components appear to be most promising in the research for prgnosticators of metastatic disease. In conclusion, the increasing knowledge of molecular genetic events involved in pathogenesis and prognosis of testicular germ cell tumors will not only help to better understand development and progression of testicular cancer, but it will also define new approaches to classification and management of germ cell tumors
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
